21 reports of this reaction
1.7% of all TRIBASIC CALCIUM PHOSPHATE reports
#10 most reported adverse reaction
HYPERSENSITIVITY is the #10 most commonly reported adverse reaction for TRIBASIC CALCIUM PHOSPHATE, manufactured by DNA Labs, Inc.. There are 21 FDA adverse event reports linking TRIBASIC CALCIUM PHOSPHATE to HYPERSENSITIVITY. This represents approximately 1.7% of all 1,206 adverse event reports for this drug.
Patients taking TRIBASIC CALCIUM PHOSPHATE who experience hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERSENSITIVITY is a less commonly reported adverse event for TRIBASIC CALCIUM PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to hypersensitivity, the following adverse reactions have been reported for TRIBASIC CALCIUM PHOSPHATE:
The following drugs have also been linked to hypersensitivity in FDA adverse event reports:
HYPERSENSITIVITY has been reported as an adverse event in 21 FDA reports for TRIBASIC CALCIUM PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERSENSITIVITY accounts for approximately 1.7% of all adverse event reports for TRIBASIC CALCIUM PHOSPHATE, making it a notable side effect.
If you experience hypersensitivity while taking TRIBASIC CALCIUM PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.